Printer Friendly

MAJOR IMPROVEMENT IN DIAGNOSIS OF HEART ATTACKS IN EMERGENCY DEPARTMENT USING CHERNE VARIANCE CARDIOGRAPH DOCUMENTED BY MINNEAPOLIS RESEARCH

MAJOR IMPROVEMENT IN DIAGNOSIS OF HEART ATTACKS IN EMERGENCY DEPARTMENT

USING CHERNE VARIANCE CARDIOGRAPH DOCUMENTED BY MINNEAPOLIS RESEARCH
 MINNEAPOLIS, Jan. 8 /PRNewswire/ -- Early diagnosis of heart attacks can be significantly improved through the use of newly developed equipment, according to a study conducted recently at Fairview Southdale Hospital.
 Results of the study are published in this month's "Annual of Emergency Medicine" in an article by David Justis, M.D., Emergency Department physician and William Hession, M.D., cardiologist and medical director of The Heart Center, both of Fairview Southdale Hospital.
 Tested was a 22-lead electrocardiogram (ECG) developed by Cherne Medical, Inc.(NASDAQ: CHNE), of Minneapolis. Currently, when a person comes into a hospital emergency room with chest pain, the electrical activity of the heart muscle is tested with 12 ECG "leads" or wires attached to the patient's chest.
 During the study, conducted in 1989, 163 patients were tested on both 22- and 12-lead ECGs in addition to other routine tests used when a heart attack is suspected. Use of the 22-lead ECG showed a significant improvement over the traditional 12-lead ECG in identifying those patients with chest pain who were actually having a heart attack.
 "That is extremely important," said Justis, "because that means the patient who has pain for reasons other than a heart attack may not have to be admitted to the hospital for costly tests, called 'rule-out testing.'"
 In the article, Justis concludes that the 22-lead ECG is accurate in diagnosing more than 97 percent of heat attacks, while reducing unnecessary hospital admissions for "rule-outs" by 69 percent.
 Cherne Medical, Inc. manufactures and markets the Cherne Variance Cardiograph, a resting, non-invasive, stress-free diagnostic instrument capable of identifying coronary artery disease even when no symptoms are present. The common stock of Cherne Medical, Inc. is traded on the national over-the-counter market under the NASDAQ symbol CHNE.
 -0- 1/8/92
 /CONTACT: David L. Printy, chairman, president and CEO of Cherne Medical, 612-933-2838/
 (CHNE) CO: Cherne Medical ST: Minnesota IN: MTC SU:


AL -- MN013 -- 7877 01/08/92 14:36 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 8, 1992
Words:342
Previous Article:CREDIT RATING DOWNGRADES OUTNUMBER UPGRADES DURING 1991 BUT FOURTH QUARTER LOOKS HOPEFUL
Next Article:LINCOLN-MERCURY PLANS CONTINUED SALES SUCCESS; INTRODUCES NEW MINIVAN, FUTURE LUXURY CAR (Product Announcement)
Topics:


Related Articles
CHERNE MEDICAL BECOMES VITAL HEART SYSTEMS; STRATEGIC MOVE TO BOSTON AREA IN AUGUST TO DEVELOP NEW PRODUCTS AND SERVICES
VITAL HEART SYSTEMS ANNOUNCES A JOINT CARDIOGRAPH DEVELOPMENT PROJECT WITH DIGITAL EQUIPMENT CORPORATION
VITAL HEART SYSTEMS LAUNCHES EUROPEAN DISTRIBUTOR NETWORK
VITAL HEART SYSTEMS REPORTS COMMUNICATION FROM FDA
VITAL HEART SYSTEMS, INC. ANNOUNCES SALE OF FOUR VARIANCE CARDIOGRAPHS TO HOSPITAL CORPORATION OF AMERICA
VITAL HEART SYSTEMS ENTERS INTO EXCLUSIVE OPTION AGREEMENT TO PURCHASE NEW TECHNOLOGY
VITAL HEART SYSTEMS ISSUED NEW PATENT
VITAL HEART SYSTEMS ANNOUNCES SALES TO NEW SCANDINAVIAN DISTRIBUTOR FOR THE FOURTH QUARTER 1992
VITAL HEART SYSTEMS ANNOUNCES MANAGEMENT REALIGNMENT
VITAL HEART SYSTEMS AND BETH ISRAEL HOSPITAL TO EVALUATE NEW INSTRUMENT FOR PATIENTS AT RISK FOR 'SUDDEN DEATH'

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters